Latest BioAge Labs News & Updates

See the latest news and media coverage for BioAge Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
BioAge Labs

Biotech developing therapies targeting metabolic aging

bioagelabs.com
Headquarters
Emeryville, United States
Founded year
2015
Company type
Public company
Number of employees
90–200
Industry
Pharmaceuticals

Last updated

Latest news about BioAge Labs

In short: BioAge Labs advanced its lead NLRP3 inhibitor, BGE-102, into Phase 2 clinical trials for cardiovascular risk and diabetic macular edema.

Company announcements

BioAge Labs

BioAge reports positive Phase 1 data for BGE-102

BGE-102 achieves ≥85% median hsCRP reductions at 60 mg and 120 mg doses in obese participants. Well tolerated. Phase 2 trials in cardiovascular risk and DME planned for mid-2026.

BioAge Labs

BioAge announces pricing of upsized $115 million public offering

Offers 5,897,435 shares at $19.50 each. Proceeds fund research, clinical development of BGE-102, NLRP3, and APJ programs. Closing expected January 23, 2026.

Unlock all announcements with a

Media coverage

Yahoo Finance

BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor

CV, a 12-week, 160-patient Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in adults with obesity, elevated inflammation, and additional cardiovascular risk factors...

Unlock all articles with a

Never miss news about BioAge Labs

Track BioAge Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioAge Labs competitors & trending companies

Browse news for competitors to BioAge Labs and other trending companies.